Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook

David Moatazedi, President and Chief Executive Officer of Evolus

“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company.”

David Moatazedi, President and Chief Executive Officer of Evolus

“Jeuveau(®) remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”

David Moatazedi, President and Chief Executive Officer of Evolus

“Global toxin revenue grew approximately 11% both in the third quarter and year to date compared with the same periods in 2025, while our global HA gel portfolio continues to advance in the market and grew revenue nearly 40% year over year in the quarter.”

David Moatazedi, President and Chief Executive Officer of Evolus

“Through the first nine months, we grew revenue 14% and improved Adjusted EBITDA by approximately $23 million compared with 2025, while continuing to gain share.”

David Moatazedi, President and Chief Executive Officer of Evolus

“Our fourth consecutive quarter of positive Adjusted EBITDA reflects our ability to sustain growth while maintaining expense discipline and investing in the portfolio.”

David Moatazedi, President and Chief Executive Officer of Evolus

“These results reinforce our confidence in our full-year 2026 financial outlook, while the anticipated FDA approval of Evolysse(®) Sculpt by year-end represents an additional opportunity to expand our portfolio and support progress toward our 2028 revenue and Adjusted EBITDA margin objectives.”

David Moatazedi, President and Chief Executive Officer of Evolus

“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity,”

David Moatazedi, President and Chief Executive Officer of Evolus

“Our partnership with IBSA to develop and commercialize Profhilo(®) in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”

David Moatazedi, President and Chief Executive Officer of Evolus

“Our recent option agreement also provides a potential entry into procedure-based injectable hair growth, a category that is highly complementary to our existing customer base.”

David Moatazedi, President and Chief Executive Officer of Evolus

“The option structure allows us to evaluate meaningful human clinical data before deciding whether to make a larger investment.”

David Moatazedi, President and Chief Executive Officer of Evolus

“By building on our commercial platform and investing selectively in new categories, we are well-positioned to serve more of our customers’ needs, expand our addressable market, and continue building a differentiated injectable aesthetics portfolio.”